AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- KRAS Altered Advanced or Metastatic Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- July 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- City of Hope National Medical Center · Duarte, CA
- University of California Los Angeles · Los Angeles, CA
Georgia · 1
- Emory University · Atlanta, GA
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Missouri · 1
- Siteman Cancer Center - Washington University · St Louis, MO
North Carolina · 1
- Duke Cancer Center · Durham, NC
Pennsylvania · 1
- Thomas Jefferson University · Philadelphia, PA
Tennessee · 1
- Sarah Cannon Research Institute Oncology Partners · Nashville, TN
Texas · 1
- Next Oncology · San Antonio, TX
Virginia · 1
- Next Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.